AbbVie Inc.
250.91USD
+2.1300 (+0.86%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $3.84▼ | $3.85 | 6 | 7 |
| Next quarter | $3.87▼ | $3.99 | 1 | 13 |
| Current year | $14.01▼ | $14.24 | 1 | 20 |
| Next year | $16.28▲ | $16.22 | 10 | 9 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $3.61 | $3.65 | +0.04 (+1.2%) |
| 2026-03-31 | $2.67 | $2.65 | -0.02 (-0.8%) |
| 2025-12-31 | $2.65 | $2.71 | +0.06 (+2.2%) |
| 2025-09-30 | $1.78 | $1.86 | +0.08 (+4.2%) |
412 ratings from 43 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Piper Sandler | Maintained | Overweight | $298 $303 | Aug 20, 2026 |
| Wells Fargo | Maintained | Overweight | $295 $300 | Aug 17, 2026 |
| Wolfe Research | Upgraded from Peer Perform | Outperform | $300 | Aug 13, 2026 |
| BNP Paribas | Maintained | Neutral | $218 $247 | Aug 11, 2026 |
| Evercore ISI Group | Maintained | Outperform | $246 $260 | Aug 10, 2026 |
| Berenberg | Maintained | Buy | $275 | Aug 6, 2026 |
| Erste Group | Upgraded from Hold | Buy | — | Aug 5, 2026 |
| Guggenheim | Maintained | Buy | $261 $288 | Aug 4, 2026 |
| Canaccord Genuity | Maintained | Buy | $282 $290 | Aug 3, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $265 $285 | Aug 3, 2026 |
| Morgan Stanley | Maintained | Overweight | $278 $296 | Aug 3, 2026 |
| TD Cowen | Maintained | Buy | $280 | Jul 31, 2026 |
| William Blair | Maintained | Buy | — | Jul 31, 2026 |
| Barclays | Maintained | Overweight | $275 $300 | Jul 29, 2026 |
| Canaccord Genuity | Maintained | Buy | $273 $282 | Jul 22, 2026 |
| Citigroup | Maintained | Neutral | $230 $260 | Jul 15, 2026 |
| UBS | Maintained | Neutral | $230 $260 | Jul 13, 2026 |
| BMO Capital | Maintained | Outperform | $258 $300 | Jul 13, 2026 |
| B of A Securities | Maintained | Buy | $234 $276 | Jul 10, 2026 |
| RBC Capital | Maintained | Outperform | $260 $280 | Jul 10, 2026 |
| Wells Fargo | Maintained | Overweight | $260 $295 | Jul 10, 2026 |
| Guggenheim | Maintained | Buy | $249 $261 | Jul 9, 2026 |
| JP Morgan | Maintained | Overweight | $260 $280 | Jul 9, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $240 $265 | Jul 6, 2026 |
| Piper Sandler | Reiterated | Overweight | $298 | Jun 23, 2026 |
69 filings from 25 insiders · 12 buy / 1 sell over 6m
Officers and directors of ABBV, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| DONOGHOE NICHOLASOfficer | Sell | 32.7k | $250.00 | $8.18M | Aug 14, 2026 |
| DONOGHOE NICHOLASOfficer | Exercise | 32.7k | $79.02 | $2.58M | Aug 14, 2026 |
| FREYMAN THOMAS CDirector | Grant | 1.1k | — | — | May 8, 2026 |
| FALK THOMAS JDirector | Grant | 1.1k | — | — | May 8, 2026 |
| AUSTIN ROXANNE SCHUHDirector | Grant | 1.1k | — | — | May 8, 2026 |
| WADDELL FREDERICK HDirector | Grant | 1.1k | — | — | May 8, 2026 |
| RAPP EDWARD JDirector | Grant | 1.1k | — | — | May 8, 2026 |
| HART BRETT JDirector | Grant | 1.1k | — | — | May 8, 2026 |
| BURNSIDE WILLIAM H LDirector | Grant | 1.1k | — | — | May 8, 2026 |
| MEYER MELODY BDirector | Grant | 1.1k | — | — | May 8, 2026 |
| ROBERTS REBECCA B.Director | Grant | 1.1k | — | — | May 8, 2026 |
| DAVIS JENNIFER LDirector | Grant | 1.1k | — | — | May 8, 2026 |
| QUAGGIN SUSAN EDirector | Grant | 1.1k | — | — | May 8, 2026 |
| PURDUE DAVID RYANOfficer | Sell | 5.2k | $233.56 | $1.22M | Mar 4, 2026 |
| SIATIS PERRY C.General Counsel | Sell | 18.7k | $233.51 | $4.38M | Mar 2, 2026 |
| SIATIS PERRY C.General Counsel | Sell | 22.4k | $230.00 | $5.15M | Feb 25, 2026 |
| SIATIS PERRY C.General Counsel | Exercise | 22.4k | $149.62 | $3.86M | Feb 25, 2026 |
| SALEKI-GERHARDT AZITAChief Operating Officer | Grant | 36.8k | — | — | Feb 18, 2026 |
| MICHAEL ROBERT A.Chief Executive Officer | Grant | 82.4k | — | — | Feb 18, 2026 |
| STEWART JEFFREY RYANOfficer | Grant | 53.7k | — | — | Feb 18, 2026 |
No analyst notes on ABBV yet.
Analyst Ratings
29 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 8 | 17 | 5 | 0 | 1 | Buy2.00 |
| 1 mo ago | 8 | 17 | 5 | 0 | 1 | Buy2.00 |
| 2 mo ago | 8 | 16 | 6 | 0 | 1 | Buy2.03 |
| 3 mo ago | 8 | 16 | 6 | 0 | 1 | Buy2.03 |